List of publications on aHUS published by aHUS Alliance:
http://www.ahusallianceaction.org/list-of-publications-on-ahus/
December 8, 2013:
New Data Presented at ASH Annual Meeting Enhance Understanding of aHUS to Provide Optimal Care for Patients
Press release here.
November 9, 2013:
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Press release here.
Feb. 19, 2015:
Omeros Corporation’s Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use – The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS –
Press release here.
July 23, 2015:
FDA Grants “Fast Track” to Omeros’ Complement Inhibitor OMS721 for aHUS
Press release here.
August 18, 2015:
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial — Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients —
Press release here.
December 2, 2015
Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor
Press release here
Press release here
September 26, 2017
Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
Press release here
Nov.3, 2017
Chemocentryx: http://www.chemocentryx.com/pipeline/orphan-and-rare-diseases/
Press release here